← All trials
NCT03799510
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2018
- Primary completion
- Aug 31, 2019
- Completion date
- Jan 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 95
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oswaldo Cruz FoundationLead sponsor
- Biomedical Research Center ESPOIR POUR LA SANTEOverall official - principal investigator
- Immune DesignCollaborator
- Oswaldo Cruz FoundationStudy chair
- Orygen Biotecnologia SACollaborator
- Biomedical Research Center ESPOIR POUR LA SANTEStudy director
- Biomedical Research Center EPLSCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.